Your fact-checks will appear here
American multinational biotechnology company
The Alzheimer’s field is poised for multiple high‑profile Phase III and confirmatory readouts in 2026, with programs ranging from next‑generation anti‑amyloid antibodies to oral small molecules and me...
No dementia drug developed or publicly tied to Elon Musk has received FDA or EMA approval as of December 2025 in the available reporting. Neuralink — the Musk-associated company most often linked to n...
Bill Gates has made personal investments aimed at Alzheimer’s research totaling about $100 million — a $50 million check to the Dementia Discovery Fund (DDF) and roughly $50 million pledged for start‑...
The available reporting documents the Dementia Discovery Fund (DDF) as a venture capital vehicle launched in 2015 to finance translational dementia research and lists its backers and fundraising miles...
Lecanemab and aducanumab are both anti–amyloid-β monoclonal antibodies approved to treat early Alzheimer’s disease, but they differ in . Lecanemab preferentially binds toxic protofibrils and shows fas...
The core factual findings are simple: Leqembi (lecanemab) received and was , after a confirmatory trial demonstrated clinical benefit . Aduhelm (aducanumab) received , and public records in the datase...
A broad pipeline of tau-based approaches—small molecules that block aggregation or modify tau chemistry, immunotherapies that target extracellular tau, gene‑ and RNA‑based tactics that lower tau produ...
Patients prescribed 2025 FDA‑approved Alzheimer’s drugs face variable but often substantial out‑of‑pocket exposure that depends on the drug’s list price, Medicare cost‑sharing rules, required diagnost...
Clinical trials reported to show cognitive benefits in recent coverage include CT1812 (zervimesine) in dementia with Lewy bodies — the SHIMMER program reported safety and “cognitive improvements” — an...
From 2020 through 2025 the U.S. Food and Drug Administration authorised only anti‑amyloid disease‑modifying therapies for Alzheimer’s — notably lecanemab (Leqembi) and donanemab (Kisunla) — while no F...
Eisai and Biogen’s lecanemab (Leqembi) program used large Phase 3 trials and extensive post‑marketing safety reviews, including an 18‑month initiation then maintenance dosing schema and multiple regul...
Neurocept is presented in consumer press as an over‑the‑counter brain‑health supplement with no published, product‑level clinical trials in the provided sources, while aducanumab and lecanemab are pre...
The FDA’s June 2021 accelerated approval of aducanumab (Aduhelm) was controversial because the agency relied on a surrogate — reduction in brain amyloid — despite trials that produced conflicting clin...
The FDA advisory committee overwhelmingly recommended against approval of Biogen’s aducanumab, with most reports saying committee members voted “no” (variously reported as 8–0 with abstentions or 10–0...
The FDA granted accelerated approval to aducanumab (brand name Aduhelm) on June 7, 2021, based on its effect in , a surrogate endpoint the agency determined was reasonably likely to predict clinical b...